MARKET

NVS

NVS

Novartis
NYSE

Real-time Quotes | Nasdaq Last Sale

93.79
-0.12
-0.13%
Pre Market: 92.99 -0.8 -0.85% 04:45 06/17 EDT
OPEN
94.34
PREV CLOSE
93.91
HIGH
94.77
LOW
93.72
VOLUME
8
TURNOVER
--
52 WEEK HIGH
98.52
52 WEEK LOW
77.04
MARKET CAP
210.57B
P/E (TTM)
26.98
1D
5D
1M
3M
1Y
5Y
CureVac Covid-19 Vaccine Candidate Disappoints in Key Study
marketwatch.com · 9h ago
Varicella Zoster Infection Treatment Market 2021 With Covid-19 Impact on Market Share, Size, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2027
The is segmented on the lines of its drug type, route of administration and regional. Basis of drug type is segmented into Acyclovir, Valacyclovir and Famciclovir. Based on route of administration it covers Oral, Topical and Injectable. The Varicella Zost...
Heraldkeepers · 13h ago
Novartis receives Breakthrough Therapy designation for prostate cancer candidate
The FDA has awarded Breakthrough Therapy designation to Novartis (NVS) for Lu-PSMA-617, its radioligand therapy under investigation for the treatment of metastatic castration-resistant prostate cancer ("mCRPC").The designation was granted based on
Seekingalpha · 14h ago
UPDATE 1-Novartis prostate cancer drug receives U.S. FDA breakthrough designation
reuters.com · 17h ago
Novartis receives FDA breakthrough therapy designation for prostate cancer treatment
reuters.com · 17h ago
Axtria Leads Discussion on Pharma's Advanced Uses of Data Analytics and Artificial Intelligence With 6 Sessions at PMSA 2021 Annual Conference
With the elevated importance of data analytics and artificial intelligence (AI)-driven intelligence technology systems for a global life sciences industry facing new risks to its commercial model accelerated by COVID-19, Axtria has announced it will be lea...
GlobeNewswire · 21h ago
Global Anti-Parkinson Drugs Market Report 2021-2030 Featuring Major Players - GlaxoSmithKline, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie and Mylan
The "Anti-Parkinson Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
GlobeNewswire · 21h ago
Owkin Welcomes Dr. Joseph Lehar as a Senior Vice President of Strategy & Business Development to Propel Platform With Strategic Partnerships
/PRNewswire/ -- Owkin announces Dr. will join the scale-up pioneering Federated Learning and AI technologies for medical research and clinical development.
PR Newswire - PRF · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVS. Analyze the recent business situations of Novartis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVS stock price target is 105.13 with a high estimate of 108.50 and a low estimate of 103.00.
EPS
Institutional Holdings
Institutions: 1.53K
Institutional Holdings: 248.95M
% Owned: 11.09%
Shares Outstanding: 2.25B
TypeInstitutionsShares
Increased
405
8.11M
New
65
1.69M
Decreased
437
16.87M
Sold Out
98
1.53M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.39%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Non-Executive Chairman/Independent Director
Joerg Reinhardt
Chief Executive Officer/Executive Board
Vasant Narasimhan
President/Chief Executive Officer
Chris Ilsley
Non-Executive Vice Chairman/Lead Director/Independent Director
Enrico Vanni
Chief Financial Officer/Executive Board
Harry Kirsch
Chief Human Resource Officer/Executive Board
Steven Baert
Corporate Executive/
Michael Ball
Chief Technology Officer/Executive Board
Steffen Lang
Chief Compliance Officer/Chief Risk Officer/Executive Board
Klaus Moosmayer
Executive Board
James Bradner
Executive Board
Shannon Klinger
Executive Board
Richard Saynor
Executive Board
Susanne Schaffert
Executive Board
John Tsai
Executive Board
Marie-France Tschudin
Executive Board
Robert Weltevreden
Secretary
Charlotte Pamer-Wieser
Non-Executive Independent Director
Nancy Andrews
Non-Executive Independent Director
Ton Buechner
Non-Executive Independent Director
Patrice Bula
Non-Executive Independent Director
Srikant Datar
Non-Executive Independent Director
Elizabeth Doherty
Non-Executive Independent Director
Ann Fudge
Non-Executive Independent Director
Bridgette Heller
Non-Executive Independent Director
Simon Moroney
Non-Executive Independent Director
Charles Sawyers
Non-Executive Independent Director
Frans van Houten
Non-Executive Independent Director
Andreas von Planta
Non-Executive Independent Director
William Winters
Declaration Date
Dividend Per Share
Ex-Div Date
01/26/2021
Dividend USD 2.0793972
03/04/2021
01/31/2020
Dividend USD 2.0067876
03/03/2020
--
Dividend USD 1.842184
03/04/2019
--
Dividend USD 1.909
03/06/2018
04/17/2017
Dividend USD 2.303
03/01/2017
04/11/2016
Dividend USD 1.766665
02/24/2016
04/14/2015
Dividend USD 2.259
03/02/2015
05/13/2014
Dividend USD 1.794
02/27/2014
04/01/2013
Dividend USD 2.057
02/26/2013
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Webull offers kinds of Novartis AG (ADR) stock information, including NYSE:NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.